J A Kemp Webinar: SPCs – Update on Recent Political and Legal Developments

2 February 2021

A Supplementary Protection Certificate (SPC) is a unique intellectual property right for active ingredients of human and veterinary medicinal products requiring marketing authorisation. Its purpose is to compensate patent holders for loss in effective patent term resulting from the time taken to receive such marketing authorisation. SPCs are available in EU/EEA member states, and other European countries including Switzerland and the UK, which (at least for now) broadly follows the legal framework set by EU regulation. This regulation specifies only four basic requirements for grant of an SPC, but each has provoked multiple referrals to the CJEU. The complex and changing interpretation of these requirements can be daunting even for seasoned professionals, and changes associated with Brexit will introduce additional complexity for the UK.

This webinar makes use of the significant experience of J A Kemp’s attorneys in filing and prosecuting SPCs across Europe, and will use case studies to illustrate our tips for preparing your patent portfolio to take maximum advantage of the SPC system and to prepare for any post-Brexit changes.

Topics will include:

• Update on recent CJEU judgments, including C-650/17 (Royalty Pharma) and C-673/18 (Santen)
• Update on SPCs in the UK post-Brexit
• Optimising patent claims for SPC purposes
• Choosing the right patent for your SPC applications
• Planning ownership for multiple SPCs
• Third party considerations

This is a technical webinar aimed at: 

• In-house IP and regulatory practitioners working in medical products, both pharmaceuticals and biopharmaceuticals / biologics
• Attorneys involved in drafting, prosecuting and advising on claims for medical products
• People involved in any stage of the development of medical products, from academic institutions to start-ups to major pharmaceutical companies

Timings

2.30pm GMT then on-demand

Speakers & Topics

Ravi Srinivasan, Partner, Patent Attorney, J A Kemp

Ravi has over 20 years of professional experience. He is known for his practical and commercial approach to patent work. He handles cases in both organic and inorganic chemistry, with particular expertise in the pharmaceutical field where he advises startup companies as well as medium-sized and large pharmaceutical companies.
 
Graham Lewis, Partner, Patent Attorney, J A Kemp

Graham works across a diverse range of biotechnology and life sciences subject matter, particularly focusing on immunology. Graham's areas of technical speciality include allergy and autoimmunity, with extensive patent drafting and prosecution experience in the fields of peptide immunotherapy, antibodies and related immunomodulatory agents, and genomics.

Registration

To book please visit the registration page.